Phoenix Pharmaceuticals

Executive Summary

Phoenix Pharmaceuticals is a privately-held, U.S.-based company established in 1993 that specializes in the manufacture and supply of high-purity research peptides and peptide-based compounds for the global life sciences community. Headquartered in Burlingame, California, the company serves as a critical supplier of custom and catalog peptides for non-clinical biochemical, immunological, and pharmacological research. With over three decades of operational history, Phoenix has built a reputation for reliability and quality in the research reagents sector, supporting academic, government, and biopharmaceutical laboratories worldwide. The company's long-standing presence and focus on custom synthesis position it as a stable, niche player in the life sciences tools market, though its private status limits public visibility into financial performance and growth trajectory.

Upcoming Catalysts (preview)

• 2027Expansion of peptide manufacturing capacity or new facility60% success
• Q4 2026Launch of novel peptide library or specialized research reagents50% success
• 2027Strategic partnership with a larger life sciences distributor40% success